Pacira BioSciences, Inc. (PCRX) dropped 6.69% to $21.48, down $1.54, after receiving a Paragraph IV certification notice from The WhiteOak Group, which filed an Abbreviated New Drug Application - ANDA challenging the patents covering Pacira's lead product EXPAREL.
WhiteOak alleges that 19 patents listed in the FDA's Orange Book are invalid or non-infringed, threatening Pacira's market exclusivity. Pacira has 45 days to file suit, which, if done, would trigger a 30-month stay of FDA approval for the generic.
The challenge raises strategic risk for Pacira's non-opioid pain platform and could affect revenue forecasts and valuation if litigation or generic competition emerges.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.